[{"id":"d5e3296e-7887-47f7-a8e8-e85cdb5b5e2b","acronym":"MORPHEUS BC","url":"https://clinicaltrials.gov/study/NCT04802759","created_at":"2021-03-17T15:57:40.908Z","updated_at":"2025-02-25T12:28:00.493Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","source_id_and_acronym":"NCT04802759 - MORPHEUS BC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ER • CDK4","pipe":" | ","alterations":" HER-2 positive • ER positive","tags":["ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (RG6171) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)"],"overall_status":"Recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-17"},{"id":"ee15de22-b96e-4782-9dfa-de6fb61fba65","acronym":"MoST-TAP","url":"https://clinicaltrials.gov/study/NCT06003621","created_at":"2023-08-22T15:08:28.367Z","updated_at":"2024-07-02T16:35:00.422Z","phase":"Phase 2","brief_title":"Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients","source_id_and_acronym":"NCT06003621 - MoST-TAP","lead_sponsor":"Omico","biomarkers":" PD-L1 • TMB • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression • PD-L1 amplification","tags":["PD-L1 • TMB • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Pegasys (pegylated interferon α -2a) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2024-05-29"},{"id":"68ced0d1-5116-4b3d-8079-1a15f3e6de8f","acronym":"FAIM","url":"https://clinicaltrials.gov/study/NCT04920708","created_at":"2021-06-11T00:54:37.032Z","updated_at":"2024-07-02T16:35:31.322Z","phase":"Phase 2","brief_title":"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression","source_id_and_acronym":"NCT04920708 - FAIM","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2 • ER • PIK3CA • PTEN • AKT1","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • PIK3CA mutation • HER-2 mutation • ER positive + HER-2 negative • CDK4 mutation","tags":["HER-2 • ER • PIK3CA • PTEN • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • PIK3CA mutation • HER-2 mutation • ER positive + HER-2 negative • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • ipatasertib (RG7440) • Pegasys (pegylated interferon α -2a)"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 12/28/2022","start_date":" 12/28/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-10-27"},{"id":"d159abba-1cb8-4c4b-979c-655d4360cdeb","acronym":"IPOS","url":"https://clinicaltrials.gov/study/NCT04798612","created_at":"2021-03-15T15:53:50.557Z","updated_at":"2024-07-02T16:35:39.694Z","phase":"Phase 2","brief_title":"Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression","source_id_and_acronym":"NCT04798612 - IPOS","lead_sponsor":"Zealand University Hospital","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 08/14/2023","start_date":" 08/14/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-17"},{"id":"c24ceb5a-a63d-4f4b-a68e-78ae3a0662b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02328755","created_at":"2021-06-22T23:53:57.959Z","updated_at":"2024-07-02T16:36:23.422Z","phase":"Phase 1/2","brief_title":"Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia","source_id_and_acronym":"NCT02328755","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 03/25/2019","primary_completion_date":" 03/25/2019","study_txt":" Completion: 03/25/2019","study_completion_date":" 03/25/2019","last_update_posted":"2021-10-06"},{"id":"168e1448-cbe1-4429-b2af-501da661483e","acronym":"MSIT","url":"https://clinicaltrials.gov/study/NCT02381379","created_at":"2021-01-18T11:20:49.268Z","updated_at":"2024-07-02T16:36:41.055Z","phase":"Phase 3","brief_title":"Malaysia Stop Tyrosine Kinase Inhibitor Trial","source_id_and_acronym":"NCT02381379 - MSIT","lead_sponsor":"Ministry of Health, Malaysia","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a)"],"overall_status":"Unknown status","enrollment":" Enrollment 118","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2020-09-14"},{"id":"fab262b8-124c-4663-b3ae-6f98de0eae86","acronym":"","url":"https://clinicaltrials.gov/study/NCT02174172","created_at":"2021-01-18T10:08:01.012Z","updated_at":"2024-07-02T16:36:45.116Z","phase":"Phase 1","brief_title":"A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT02174172","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF • ALK • PD-1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • BRAF V600 • ALK rearrangement","tags":["BRAF • ALK • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • BRAF V600 • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Gazyva (obinutuzumab) • Pegasys (pegylated interferon α -2a) • Roferon A (recombinant interferon alfa-2a)"],"overall_status":"Completed","enrollment":" Enrollment 158","initiation":"Initiation: 08/18/2014","start_date":" 08/18/2014","primary_txt":" Primary completion: 11/25/2019","primary_completion_date":" 11/25/2019","study_txt":" Completion: 11/25/2019","study_completion_date":" 11/25/2019","last_update_posted":"2020-05-12"},{"id":"c2127c94-b5aa-4264-be7a-ee93fa6a03a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01259856","created_at":"2021-01-18T05:04:56.061Z","updated_at":"2024-07-02T16:37:00.069Z","phase":"Phase 3","brief_title":"Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)","source_id_and_acronym":"NCT01259856","lead_sponsor":"Ronald Hoffman","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 168","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 06/30/2017","primary_completion_date":" 06/30/2017","study_txt":" Completion: 06/30/2017","study_completion_date":" 06/30/2017","last_update_posted":"2019-04-30"},{"id":"3629edc5-f527-4087-a4f7-97f634c0b8f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01544920","created_at":"2022-07-18T07:54:24.897Z","updated_at":"2024-07-02T16:37:07.027Z","phase":"Phase 3","brief_title":"Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)","source_id_and_acronym":"NCT01544920","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" IFNL3","pipe":"","alterations":" ","tags":["IFNL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 737","initiation":"Initiation: 05/30/2012","start_date":" 05/30/2012","primary_txt":" Primary completion: 05/19/2015","primary_completion_date":" 05/19/2015","study_txt":" Completion: 05/19/2015","study_completion_date":" 05/19/2015","last_update_posted":"2018-09-11"},{"id":"4debac25-5f39-463e-8915-abc74602ad24","acronym":"","url":"https://clinicaltrials.gov/study/NCT01259817","created_at":"2021-01-18T05:04:55.274Z","updated_at":"2024-07-02T16:37:26.611Z","phase":"Phase 2","brief_title":"Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)","source_id_and_acronym":"NCT01259817","lead_sponsor":"Ronald Hoffman","biomarkers":" JAK2 • CALR","pipe":" | ","alterations":" JAK2 V617F","tags":["JAK2 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 V617F"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • hydroxyurea • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 135","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2017-01-11"},{"id":"7b9fa6ec-f256-4260-a160-7871d909739f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02736721","created_at":"2021-01-18T13:24:13.722Z","updated_at":"2024-07-02T16:37:29.004Z","phase":"Phase 3","brief_title":"Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)","source_id_and_acronym":"NCT02736721","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 09/01/2003","start_date":" 09/01/2003","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 11/01/2010","study_completion_date":" 11/01/2010","last_update_posted":"2016-09-20"}]